Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02052726 · ClinicalTrials.gov registry record · Phase 1
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 184
- Enrollment target
NCT02052726 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 184 participants.
The verdict
NCT02052726, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 184 participants
- Enrollment target
Study Summary
This study will investigate a clostridium difficile vaccine in healthy adults aged 50 to 85 years, who will each receive 3 doses of vaccine. Subjects will receive their vaccine doses at either months 0, 1, and 3 or days 1, 8, and 30. Subjects will be divided into 2 age groups (50-64 and 65-85 years of age). The study will assess how safe and tolerable the vaccine is, and also look at subjects' immune response to the vaccine.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL placebo
- BIOLOGICAL C. difficile vaccine with adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2014-01-22 |
| Est. Completion | 2015-05-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02052726
The ClinicalTrials.gov registry entry for NCT02052726 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02052726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02052726 about?
NCT02052726 is a clinical study titled "A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.". This study will investigate a clostridium difficile vaccine in healthy adults aged 50 to 85 years, who will each receive 3 doses of vaccine. Subjects will receive their vaccine doses at either months 0, 1, and 3 or days 1, 8, and 30. Subjects will be divided into 2 age groups (50-64 and 65-85 years ...
What is the current status of trial NCT02052726?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 184 participants. The study started on 2014-01-22. Estimated completion is 2015-05-05.
What interventions are being tested in trial NCT02052726?
The interventions under investigation include: Placebo (BIOLOGICAL), placebo (BIOLOGICAL), C. difficile vaccine with adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT02052726?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.